493 related articles for article (PubMed ID: 26375549)
61. MAP Kinase-Interacting Kinase 1 Promotes Proliferation and Invasion of Hepatocellular Carcinoma and Is an Unfavorable Prognostic Biomarker.
Wang X; Wang Y; Zhang Q; Zhuang H; Chen B
Med Sci Monit; 2018 Mar; 24():1759-1767. PubMed ID: 29576605
[TBL] [Abstract][Full Text] [Related]
62. High expression of VRK1 is related to poor prognosis in glioma.
Ben Z; Gong L; Qiu Y
Pathol Res Pract; 2018 Jan; 214(1):112-118. PubMed ID: 29103766
[TBL] [Abstract][Full Text] [Related]
63. Comprehensively prognostic and immunological analysis of VRK Serine/Threonine Kinase 1 in pan-cancer and identification in hepatocellular carcinoma.
Chen D; Zhou W; Chen J; Wang J
Aging (Albany NY); 2023 Dec; 15(24):15504-15524. PubMed ID: 38157278
[TBL] [Abstract][Full Text] [Related]
64. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
65. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma.
Wang W; Jia WD; Hu B; Pan YY
Oncotarget; 2017 Apr; 8(16):26434-26447. PubMed ID: 28460436
[TBL] [Abstract][Full Text] [Related]
66. Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.
Chen L; Tian H; Li M; Ge C; Zhao F; Zhang L; Li H; Liu J; Wang T; Yao M; Li J
Tumour Biol; 2016 May; 37(5):5951-61. PubMed ID: 26596832
[TBL] [Abstract][Full Text] [Related]
67. Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic Apoptotic Pathways in Hepatocellular Carcinoma Cells.
Chiang IT; Chen WT; Tseng CW; Chen YC; Kuo YC; Chen BJ; Weng MC; Lin HJ; Wang WS
Anticancer Res; 2017 Jan; 37(1):161-167. PubMed ID: 28011486
[TBL] [Abstract][Full Text] [Related]
68. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis.
Calvisi DF; Ladu S; Pinna F; Frau M; Tomasi ML; Sini M; Simile MM; Bonelli P; Muroni MR; Seddaiu MA; Lim DS; Feo F; Pascale RM
Gastroenterology; 2009 Nov; 137(5):1816-26.e1-10. PubMed ID: 19686743
[TBL] [Abstract][Full Text] [Related]
69. PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
Yang H; Zhao X; Zhao L; Liu L; Li J; Jia W; Liu J; Huang G
Oncotarget; 2016 Nov; 7(44):72131-72147. PubMed ID: 27708221
[TBL] [Abstract][Full Text] [Related]
70. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
[TBL] [Abstract][Full Text] [Related]
71. Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma.
Tan X; Liao Z; Liang H; Chen X; Zhang B; Chu L
Int J Oncol; 2018 Nov; 53(5):1913-1926. PubMed ID: 30226588
[TBL] [Abstract][Full Text] [Related]
72. A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression.
Chen H; Hu L; Luo Z; Zhang J; Zhang C; Qiu B; Dong L; Tan Y; Ding J; Tang S; Shen F; Li Z; Wang H
Mol Cancer; 2015 Nov; 14():186. PubMed ID: 26538215
[TBL] [Abstract][Full Text] [Related]
73. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
74. Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associated with Poor Prognosis.
Li R; Jiang X; Zhang Y; Wang S; Chen X; Yu X; Ma J; Huang X
Arch Med Res; 2019 Jan; 50(1):10-17. PubMed ID: 31101236
[TBL] [Abstract][Full Text] [Related]
75. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
76. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
[TBL] [Abstract][Full Text] [Related]
77. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.
Peng YY; He YH; Chen C; Xu T; Li L; Ni MM; Meng XM; Huang C; Li J
Cancer Lett; 2016 Jun; 376(1):10-21. PubMed ID: 26975630
[TBL] [Abstract][Full Text] [Related]
78. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth.
Liu AW; Cai J; Zhao XL; Jiang TH; He TF; Fu HQ; Zhu MH; Zhang SH
Clin Cancer Res; 2011 Feb; 17(4):710-20. PubMed ID: 21196414
[TBL] [Abstract][Full Text] [Related]
79. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
80. Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1).
Zhao Y; Tang Q; Ni R; Huang X; Wang Y; Lu C; Shen A; Wang Y; Li C; Yuan Q; Chen H; Cheng C; He S
Hum Pathol; 2013 Mar; 44(3):365-73. PubMed ID: 22995332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
